#United States #New York #Pomerantz LLP #Regeneron Pharmaceuticals #Investor Alert

Overview

Recently, Pomerantz LLP, a prominent law firm in the realm of corporate and securities class action litigation, announced it is investigating claims concerning Regeneron Pharmaceuticals, Inc., a leading biotechnology company listed on NASDAQ under the ticker REGN. The investigation aims to address potential concerns about securities fraud and unlawful business practices within the company, particularly in light of recent unfavorable news regarding its clinical trials.

The Investigation

This investigation arises from complaints voiced by investors who are concerned about possible misconduct or misrepresentation by Regeneron's executives and directors. Investors who believe they may have been adversely affected by the company’s actions are encouraged to reach out to the firm for guidance and potential participation in a class action.

Recent Developments

On May 15, 2026, Regeneron Pharmaceuticals announced disappointing results from a Phase 3 clinical trial evaluating the efficacy of their drug fianlimab, in combination with cemiplimab, for treating unresectable locally advanced or metastatic melanoma. The trial failed to meet the primary endpoint of improving progression-free survival compared to pembrolizumab, a commonly used PD-1 inhibitor. Following this announcement, Regeneron's stock plummeted by $68.57, a 9.82% drop, closing at $629.68 per share the following day. This steep decline sent shockwaves through the investor community, amplifying calls for transparency and accountability from the company's leadership.

Pomerantz LLP’s Role

Founded by the late Abraham L. Pomerantz, the firm has a storied history of advocating for the rights of investors, especially in cases of corporate misconduct and securities fraud. With offices spanning multiple major cities including New York, Chicago, and London, Pomerantz has established itself as a leader in this field, successfully recovering significant damages for investors who have suffered from corporate wrongdoing.

How to Get Involved

Investors who are concerned about their investments in Regeneron Pharmaceuticals are strongly urged to contact Danielle Peyton at Pomerantz LLP to learn more about the ongoing investigation and explore their options. The firm’s direct contact information for potential class action participants includes the email [email protected] and the phone number 646-581-9980, ext. 7980. This inquiry serves as a critical opportunity for affected investors to understand their rights and to seek justice for any financial harm incurred.

Conclusion

The ongoing investigation by Pomerantz LLP underscores the importance of corporate transparency and accountability, especially in the biotechnology sector where clinical trial results can significantly impact stock prices. As investors continue to react to the implications of Regeneron’s recent announcements, it remains essential for all stakeholders to stay informed about developments in this investigation and its potential outcomes. For those adversely affected, there remains a path to seek reassurance and potential restitution through legal channels.

For more information and updates on this matter, please stay tuned and consider reaching out to Pomerantz LLP with any questions or concerns regarding your investment.